Cargando…

Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series

Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harris, Jessica P, Postow, Michael A, Faleck, David M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982418/ https://www.ncbi.nlm.nih.gov/pubmed/35380715 http://dx.doi.org/10.1093/oncolo/oyac019

Ejemplares similares

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
por: Hisamatsu, Tadakazu, et al.
Publicado: (2018)

Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis
por: O’Connell, Jim, et al.
Publicado: (2022)

Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
por: Shimizu, Hiromichi, et al.
Publicado: (2021)

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
por: Savelkoul, Edo H J, et al.
Publicado: (2022)

Efficacy and safety of low-dose thalidomide combined with mesalazine in the treatment of refractory ulcerative colitis in adults
por: Chen, Jun-Rong, et al.
Publicado: (2022)

Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study
por: Torii, Hideshi, et al.
Publicado: (2016)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
por: Zou, Fangwen, et al.
Publicado: (2021)

Infliximab Induction Strategies in Corticosteroid-Refractory Acute Severe Ulcerative Colitis: A Case Series and Literature Review
por: Antunes, Pedro Bernardes, et al.
Publicado: (2022)

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
por: Magro, Fernando, et al.
Publicado: (2017)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
por: Kaneoka, Ayaka, et al.
Publicado: (2022)

Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience
por: Yamada, Satoshi, et al.
Publicado: (2014)

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
por: Araujo, Daniel V., et al.
Publicado: (2021)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Sacral neuromodulation for refractory ulcerative colitis: safety and efficacy in a prospective observational series of eight patients
por: Drissi, Farouk, et al.
Publicado: (2023)

Efficacy and safety of rapid escalation of cabergoline in comparison to conventional regimen for macroprolactinoma: A prospective, randomized trial
por: Rastogi, Ashu, et al.
Publicado: (2012)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

The Styrene Metabolite, Phenylglyoxylic Acid, Induces Striatal-Motor Toxicity in the Rat: Influence of Dose Escalation/Reduction over Time
por: Terre’Blanche, Gisella, et al.
Publicado: (2010)

A Type II Segmental Vitiligo Developed under Infliximab Treatment for Ulcerative Colitis
por: Ryu, Tae Hyung, et al.
Publicado: (2017)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

High Dose Infliximab in the Treatment of Refractory Uveitis: Does Dose Matter?
por: Sukumaran, Sukesh, et al.
Publicado: (2012)

Efficacy and safety of rituximab biosimilar in refractory lupus
por: Pongtarakulpanit, Nantakarn, et al.
Publicado: (2020)

A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively
por: Delasos, Lukas, et al.
Publicado: (2019)

Infliximab in the treatment of refractory uveitis. Does dose really matter?
por: Sukumaran, MD Sukesh, et al.
Publicado: (2011)

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2019)

Effect of Intra-arterial Balloon Pumping for Refractory Septic Cardiomyopathy: A Case Series
por: Takahashi, Yuji, et al.
Publicado: (2019)

Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report
por: Nassri, Ammar B, et al.
Publicado: (2019)

A Case Series of Refractory Cutaneous Sarcoidosis Successfully Treated with Infliximab
por: Tuchinda, Papapit, et al.
Publicado: (2012)

Brain Inflammation in an Infant With Hemimegalencephaly, Escalating Seizures, and Epileptic Encephalopathy
por: Kim, Se Hee, et al.
Publicado: (2016)

Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients
por: Hao, Yue, et al.
Publicado: (2022)

Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis
por: Ida, Tomoaki, et al.
Publicado: (2023)

Infliximab for the treatment of refractory scleritis
por: Doctor, Priyanka, et al.
Publicado: (2009)

Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility)
por: Higginson, Irene J, et al.
Publicado: (2020)

Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis
por: Liu, Yi-Juan, et al.
Publicado: (2018)

Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis
por: Jia, Xuemei, et al.
Publicado: (2020)

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS
por: Albino, L, et al.
Publicado: (2022)

Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment
por: Loo, Kimberly, et al.
Publicado: (2022)

Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
por: Baruah, Manash P., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g19ebdcutqdv34kkt42cpa5a8d